Prostate Specific Antigen Isoforms and Human Glandular Kallikrein 2—Which Offers the Best Screening Performance in a Predominantly Black Population?
- 1 January 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 175 (1), 104-107
- https://doi.org/10.1016/s0022-5347(05)00069-8
Abstract
Free prostate specific antigen, complexed PSA and human glandular kallikrein 2 have independently been tested against the gold standard of total PSA for prostate cancer screening in largely white populations. With the incidence of prostate cancer much higher in black men, we sought to evaluate these markers simultaneously in a predominantly black population. A total of 138 men, of whom 108 were black, underwent ultrasound guided biopsy of the prostate for tPSA levels greater than 2.5 ng/ml or an abnormal digital rectal examination. Sera were drawn before biopsy and analyzed for tPSA, fPSA, cPSA and hK2 concentrations using standard methods (hK2 assay is for research use only, not for use in diagnostic procedures). The areas under the receiver operator characteristic curves were determined for each marker as well as biomarker combinations. Additionally, each parameter’s specificity, positive and negative predictive values, and theoretical screening efficiency were assessed at or above the 95% sensitivity level. A total of 43 (31.1%) men had prostate cancer by biopsy. While the AUC for %fPSA was statistically the highest (0.822, p <0.001), cPSA offered the highest specificity (31.6%) and positive predictive power (31.7%) of any of the tested biomarkers at comparable sensitivity (greater than 95%). The calculated efficiency of cPSA (51.4%) was also higher than the other markers. Nearly 20% of biopsies would be avoided using cPSA vs standard tPSA screening methods. Comparing the major PSA isoforms and hK2, cPSA alone appears to offer superior diagnostic discrimination for cancer detection in a predominantly black population.Keywords
This publication has 13 references indexed in Scilit:
- Applying complexed prostate-specific antigen to clinical practiceUrology, 2004
- Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical TrialJournal of Urology, 2003
- Screening for Prostate Cancer in High Risk PopulationsJournal of Urology, 2002
- Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trialUrology, 2002
- Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigenUrology, 2002
- Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communitiesThe Prostate, 2002
- Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaUrology, 2001
- Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greaterUrology, 2000
- PERCENT FREE PROSTATE SPECIFIC ANTIGEN AND CANCER DETECTION IN BLACK AND WHITE MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN 2.5 TO 9.9 NG./ML.Journal of Urology, 2000
- Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trialUrology, 2000